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enetic Screening and
isk Assessment in
ypertrophic Cardiomyopathy*
alum A. MacRae, MB, CHB, PHD,
atrick T. Ellinor, MD, PHD
oston, Massachusetts
nherited cardiovascular diseases in which sudden death
ay be the initial clinical presentation pose two basic
uestions for the cardiologist. First, how should we screen
amily members for disease? Second, once someone has
een identified through screening, how should they be
reated and, specifically, what is their risk of sudden death?
hese questions have proven difficult to answer, despite the
emarkable advances in our understanding of the molecular
asis for cardiovascular disease (1).
See page 2315
NTRINSIC BIASES IN INHERITED DISEASE
n large measure, the difficulty in addressing such clinical
uestions is a result of several intrinsic features of these
endelian disorders. The high incidence of premature
udden death, particularly if it occurs before reproductive
ge, is a major cause of the various forms of heterogeneity
een in inherited cardiac disease. The intense selective
ressure of such a phenotype cannot be underestimated.
ultiple genes may result in very similar phenotypes,
ossibly because the pathways affected are uniquely sensitive
o perturbation. This genetic heterogeneity is well docu-
ented in hypertrophic cardiomyopathy (HCM), the
ong-QT syndrome, and arrhythmogenic right ventricular
ysplasia (1). As the most malignant mutations will rapidly
e eliminated from the population, these disorders are
redicted to have a high frequency of de novo mutations and
herefore are likely to be relatively uncommon. For any
iven gene, each affected family is likely to exhibit a different
utation (allelic heterogeneity), which also may be a source
f phenotypic variation. Highly morbid genes paradoxically
ay affect multiple generations only when the effects of a
pecific mutation are modified, as more penetrant mutations
ill result in significant lethality. Thus, kindreds in which
here is a family history may already be preselected for
elatively “mild” mutations and more likely to display a
road range of different phenotypes, or pleiotropy, exhibit-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.t
From the Cardiovascular Research Center and Cardiac Arrhythmia Service,
assachusetts General Hospital, Boston, Massachusetts.ng exquisite sensitivity to genetic or environmental modi-
ers. This is perhaps most extreme in congenital heart
isease, where the pleiotropy is such that often only the
irected evaluation of apparently normal family members
ncovers any evidence of an inherited familial predisposition
2).
The net effect of these biases is that standard epidemio-
ogic approaches to defining diagnostic criteria and assessing
isk are extremely difficult to interpret. The conflicting
ublished data, both clinical and genetic, in syndromes such
s HCM to a large extent reflect real differences in study
ohorts. There is substantive variation between studies in
he mode of subject recruitment or the representation of
ndividual families, genes, and alleles, each of which are
undamental confounders.
ENETIC STUDIES
he identification of disease genes, through genetic map-
ing and positional cloning, requires large extended fami-
ies, which often may not perfectly reflect the disease seen in
ndividual patients as a result of biologic or referral biases.
owever, these fundamental studies are critical to establish
he causality of mutations and to enable the generation of
echanistically faithful disease models (1). Once the causal
enes have been defined, investigators have gone on to study
ollections of families that map to these loci. Documenta-
ion of the spectrum of mutations has also led to a greater
nderstanding of the role of specific protein domains in the
athogenesis of the respective syndromes. These studies also
ffer initial estimates of the proportion of disease attribut-
ble to each locus, the disease penetrance, and potential
enotype-phenotype correlations (3).
In HCM such studies have defined some significant
ifferences between the phenotypes seen at various loci.
owever, taken as a whole, genotype-phenotype correla-
ions have produced rather disparate results. The unavoid-
ble inclusion of multiple subjects from small numbers of
arge families has compounded the biases outlined earlier.
hen combined with the confounding effects of shared
enetic background or environmental exposures, the lack of
onsistency is not surprising (4).
The ideal study design for genotype-phenotype correla-
ion would include large numbers of unrelated subjects
both clinically affected and silent) with identical mutations.
lthough such a study is not feasible in HCM (several
roups have begun to screen large series of patients for
utations), as sequencing costs have fallen and other
heaper screening technologies have become more estab-
ished (5,6). These studies, although still limited, offer a
omplementary perspective to that obtained from earlier
amily studies. The emerging picture is of a lack of predic-
ive utility for genotyping in patients with HCM.
In this issue of the Journal, Mogensen et al. (7) presenthe first results from a hybrid design that combines serial
p
T
a
l
s
c
i
b
n
g
o
f
o
m
i
s
b
t
s
a
s
t
r
k
p
O
s
m
i
a
b
s
p
r
S
A
g
t
d
i
i
i
t
d
d
e
t
g
m
s
r
w
i
w
i
p
b
g
w
o
b
o
b
c
t
C
I
r
a
t
I
t
o
c
r
h
t
e
o
s
t
t
v
a
T
T
o
p
b
c
g
r
p
n
g
f
u
a
g
r
2327JACC Vol. 44, No. 12, 2004 MacRae and Ellinor
December 21, 2004:2326–8 Editorial Commentrobands and their families, known as a “kin-cohort” study.
his design collects multiple subjects with each mutation,
nd importantly, includes the two clinically relevant popu-
ations: those with clinical disease and their relatives. The
ize and scope of this effort, the first systematic study of
ardiac troponin I mutations in HCM, are commendable,
nvolving a thorough cardiovascular evaluation of the pro-
ands as well as affected and unaffected family members in
early 750 families over a 10-year period.
What has emerged? The study reinforces the findings of
enetic and allelic heterogeneity seen in other large studies
f this form of cardiomyopathy. Comprehensive screening
or cardiac troponin I mutations revealed abnormalities in
nly 3.1% of families. Thirteen distinct cardiac troponin I
utations in 23 probands and 77 family members were
dentified. Widely varying clinical presentations were ob-
erved not only between families with identical mutations,
ut also within families. The investigators concluded that
here were no discernible patterns of a gene- or mutation-
pecific phenotype. Of note, large families are the exception
nd not the rule in HCM, precluding an initial mapping
tage in the routine evaluation for mutations.
Ultimately, these investigators will extend their screening
o the other genes implicated in HCM. The challenge
emains how to extract meaningful information from such
in-cohorts, where the biological influences on proband
resentation and family size remain potent sources of bias.
ptimally, the ascertainment of the proband’s relatives
hould be blinded to the affection status of each family
ember. Novel statistical or biologic strategies for extract-
ng clinically useful information from monogenic families
re needed. Concepts such as transmissible lifetime risk may
e useful, but it could take several generations for a study
uch as this to collect sufficient data.
What then are the implications of the genotype-
henotype studies published to date for both screening and
isk assessment?
CREENING
t the present time, if an inexpensive, sensitive, and specific
enetic test for HCM existed, the benefits would include
he identification of asymptomatic carriers at risk for sudden
eath and obviation of the need for conventional screening
n genotypically unaffected family members. Eventually, the
dentification of asymptomatic carriers may be useful for
mplementing validated preventive strategies.
Unfortunately, all the available data suggest that such a
est simply does not exist. Hypertrophic cardiomyopathy
isplays such genetic and allelic heterogeneity that only
iscovery technologies offer the ability to detect mutations
ven in the known genes. The sensitivity and specificity of
hese techniques are not known for most of the relevant
enes, and more than 20% of HCM is not explained by
utations in these genes. It is far from clear how isolated
equence abnormalities in affected subjects, which may be gare polymorphisms of no consequence, can be interpreted
ithout functional assays for each gene. This is particularly
mportant in the interpretation of genotype in those patients
ho have potential mutations in more than one gene, an
ssue in a significant number of those screened (5,8). The
sychological impact on those who are genotype-positive
ut not yet affected must be balanced with the benefit for
enotype-negative family members, and careful counseling
ill be essential both before and after testing (9).
Objective data on those who are genotype-negative,
bserved rates of “progression” to disease, the risks of events
efore diagnosis, and comparison of genotyping with state-
f-the-art clinical diagnostic techniques will be required
efore any of these questions can be answered. At present,
linical and genetic screening can be recommended only in
he context of ongoing evaluation at a research center (4).
HARACTERIZATION OF RISK
f genetic testing is to offer any benefit in the assessment of
isk, then individual genotypes must be useful over and
bove the simple diagnosis of HCM. The data presented in
his issue of the Journal suggest that, at least for troponin
-associated disease, genotypic information allows one only
o discriminate those who have inherited any risk (and then
nly in those in whom a mutation can be detected using
urrent technology), but does not allow gradation of that
isk. In this study, all those family members who went on to
ave a cardiac arrest were detectable by conventional elec-
rocardiographic or echocardiographic screening. Mogensen
t al. (7) reasonably conclude that genetic testing offers no
bvious benefit to those who are genotype positive.
Similar conclusions have emerged from the other large
tudies of genotype-phenotype correlation irrespective of
heir design. The available data do not yet support geno-
yping as a tool in risk stratification (4), but once again, it is
ital that such data continue to be collected in the context of
ctive research.
HE FUTURE
here is so much variation in conventional phenotypes and
utcomes in many Mendelian disorders that current ap-
roaches to genotype-phenotype correlation may be incapa-
le of generating clinically useful information. A substantial
hange in our understanding of phenotypic variation with
enotype and its transmission through families will be
equired before the promised genetic revolution can take
lace. There is in vitro evidence of mechanistic heteroge-
eity even with different mutations in the same gene, and
enetic or environmental modifiers may contribute to pro-
ound differences between subjects in the same family. The
se of animal models to map and clone modifier genes is
lready underway. However, if we are to establish robust
enotype-phenotype correlations, we need to identify and
efine new phenotypes at the same time as we improve our
enotyping capabilities. A systematic search for novel phe-
n
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Editorial Comment December 21, 2004:2326–8otypes closer to the proximate cause of HCM may help.
ore precise understanding of functional groupings may be
easible using in vitro analyses or even patient-based cellular
rofiling. Functional assays may be better predictors of out-
ome, allowing the integration of multiple factors, including
enotypes at all the sarcomeric gene loci, remote modifiers,
nvironmental effects, and even potential therapies.
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